|Bid||268.90 x 0|
|Ask||269.20 x 0|
|Day's range||268.65 - 269.50|
|52-week range||28.63 - 313.00|
|Beta (5Y monthly)||1.58|
|PE ratio (TTM)||15.74|
|Earnings date||24 Feb 2021 - 01 Mar 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||23 Apr 2020|
|1y target est||264.08|
Caesars in September had agreed to buy the gambling group for 2.9 billion pounds ($3.82 billion) to expand in the fast-growing U.S. sports-betting market, after beating out Apollo. The possibility of Apollo firming up its bid faded after Caesars made it clear it could terminate the deal, if William Hill decided to proceed with another offer from rival parties mentioned in a list set by Caesars.
Caesars Entertainment (NASDAQ: CZR) saw a 22% rebound in September, likely related both to its ESPN partnership and its announced acquisition plans for English sportsbook company William Hill (LSE: WMH). While Caesars isn't faring badly in its recovery, its stock still hasn't regained the full value it had before the coronavirus struck. With the earliest possible release of COVID-19 vaccines in the U.S. still roughly two months away, according to a recent estimate from Dr. Anthony Fauci, Fools investing in consumer discretionary stocks might want to weigh several factors before buying shares of Caesars.
William Hill expects to take hit from shock sport results behind closed doorsBetting income gradually returning to pre-Covid levels, says bookmaker * Coronavirus – latest updates * See all our coronavirus coverage